Literature DB >> 23689710

HIV-1 resistance mechanism to an electrostatically constrained peptide fusion inhibitor that is active against T-20-resistant strains.

Kazuki Shimane1, Kumi Kawaji, Fusako Miyamoto, Shinya Oishi, Kentaro Watanabe, Yasuko Sakagami, Nobutaka Fujii, Kazuya Shimura, Masao Matsuoka, Mitsuo Kaku, Stefan G Sarafianos, Eiichi N Kodama.   

Abstract

T-20EK is a novel fusion inhibitor designed to have enhanced α-helicity over T-20 (enfuvirtide) through engineered electrostatic interactions between glutamic acid (E) and lysine (K) substitutions. T-20EK efficiently suppresses wild-type and T-20-resistant variants. Here, we selected T-20EK-resistant variants. A combination of L33S and N43K substitutions in gp41 were required for high resistance to T-20EK. While these substitutions also caused resistance to T-20, they did not cause cross-resistance to other known fusion inhibitors.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23689710      PMCID： PMC3719727          DOI： 10.1128/AAC.00237-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  35 in total

1.  Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.

Authors:  Jacqueline D Reeves; Stephen A Gallo; Navid Ahmad; John L Miamidian; Phoebe E Harvey; Matthew Sharron; Stefan Pohlmann; Jeffrey N Sfakianos; Cynthia A Derdeyn; Robert Blumenthal; Eric Hunter; Robert W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-20       Impact factor: 11.205

2.  Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.

Authors:  Daisuke Nameki; Eiichi Kodama; Mieko Ikeuchi; Naoto Mabuchi; Akira Otaka; Hirokazu Tamamura; Mutsuhito Ohno; Nobutaka Fujii; Masao Matsuoka
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  A simple, rapid, and sensitive system for the evaluation of anti-viral drugs in rats.

Authors:  Xiaoguang Li; Hua Qian; Fusako Miyamoto; Takeshi Naito; Kumi Kawaji; Kazumi Kajiwara; Toshio Hattori; Masao Matsuoka; Kentaro Watanabe; Shinya Oishi; Nobutaka Fujii; Eiichi N Kodama
Journal:  Biochem Biophys Res Commun       Date:  2012-06-23       Impact factor: 3.575

4.  Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41.

Authors:  L Xu; A Pozniak; A Wildfire; S A Stanfield-Oakley; S M Mosier; D Ratcliffe; J Workman; A Joall; R Myers; E Smit; P A Cane; M L Greenberg; D Pillay
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

5.  Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor.

Authors:  Chris E Baldwin; Rogier W Sanders; Yiqun Deng; Suzanne Jurriaans; Joep M Lange; Min Lu; Ben Berkhout
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

6.  T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.

Authors:  Jacob P Lalezari; Nicholaos C Bellos; Kunthavi Sathasivam; Gary J Richmond; Calvin J Cohen; Robert A Myers; David H Henry; Claire Raskino; Tom Melby; Hugh Murchison; Ying Zhang; Rebecca Spence; Michael L Greenberg; Ralph A Demasi; G Diego Miralles
Journal:  J Infect Dis       Date:  2005-02-22       Impact factor: 5.226

7.  Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity.

Authors:  Jacqueline D Reeves; John L Miamidian; Mark J Biscone; Fang-Hua Lee; Navid Ahmad; Theodore C Pierson; Robert W Doms
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.

Authors:  Adriano Lazzarin; Bonaventura Clotet; David Cooper; Jacques Reynes; Keikawus Arastéh; Mark Nelson; Christine Katlama; Hans-Jürgen Stellbrink; Jean-François Delfraissy; Joep Lange; Les Huson; Ralph DeMasi; Cynthia Wat; John Delehanty; Claude Drobnes; Miklos Salgo
Journal:  N Engl J Med       Date:  2003-05-29       Impact factor: 91.245

9.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

Authors:  C Wild; T Oas; C McDanal; D Bolognesi; T Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

10.  Helix stabilization by Glu-...Lys+ salt bridges in short peptides of de novo design.

Authors:  S Marqusee; R L Baldwin
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205
View more
  5 in total

1.  Mechanism of HIV-1 Resistance to an Electronically Constrained α-Helical Peptide Membrane Fusion Inhibitor.

Authors:  Xiyuan Wu; Zixuan Liu; Xiaohui Ding; Danwei Yu; Huamian Wei; Bo Qin; Yuanmei Zhu; Huihui Chong; Sheng Cui; Yuxian He
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

2.  Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.

Authors:  Danwei Yu; Xiaohui Ding; Zixuan Liu; Xiyuan Wu; Yuanmei Zhu; Huanmian Wei; Huihui Chong; Sheng Cui; Yuxian He
Journal:  J Biol Chem       Date:  2018-06-21       Impact factor: 5.157

3.  Anti-HIV-1 activity determined by β-galactosidase activity in the multinuclear activation of an indicator assay is comparable with that by a conventional focus counting method.

Authors:  Fusako Miyamoto; Kumi Kawaji; Shinya Oishi; Nobutaka Fujii; Mitsuo Kaku; Eiichi N Kodama
Journal:  Antivir Chem Chemother       Date:  2015-11-02

4.  Sulfono-γ-AA modified peptides that inhibit HIV-1 fusion.

Authors:  Olapeju Bolarinwa; Meng Zhang; Erin Mulry; Min Lu; Jianfeng Cai
Journal:  Org Biomol Chem       Date:  2018-10-31       Impact factor: 3.876

5.  Identification of an Antiretroviral Small Molecule That Appears To Be a Host-Targeting Inhibitor of HIV-1 Assembly.

Authors:  Jonathan C Reed; Dennis Solas; Anatoliy Kitaygorodskyy; Beverly Freeman; Dylan T B Ressler; Daryl J Phuong; J Victor Swain; Kent Matlack; Clarence R Hurt; Vishwanath R Lingappa; Jaisri R Lingappa
Journal:  J Virol       Date:  2021-01-13       Impact factor: 5.103
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.